tients with PAH has yet not been elucidated. The aim of the current study was to examine the effect of bosentan on plasma ET-1 concentrations in patients with PAH and the relationship between changes in plasma ET-1 concentrations and the clinical state of PAH patients.
Methods

Participants
Seven PAH patients, 2 men and 5 women, aged 22 to 70 years old (mean 53±20 years old) were included in the present study. Patients were eligible for enrollment if they: (1) had symptomatic, severe primary or secondary PH, (2) were in functional class 2 or higher despite conventional therapy, and (3) met the following hemodynamic criteria; mean pulmonary artery pressure (PAP) >25 mmHg at rest and mean pulmonary capillary wedge pressure <15 mmHg. Exclusion criteria were past myocardial infarction, renal failure with a plasma creatinine concentration >2.0 mg/dl and abnormal liver function. The Ethics Committee of Osaka University Hospital approved the study, and written informed consent was given by each enrolled patient.
Clinical and Laboratory Examination
Exercise capacity was evaluated by 6-min walk distance (6MWD) according to a standard protocol. Systolic PAP was assessed by maximal tricuspid regurgitation jet velocity, measured as the peak regurgitant velocity in a continuous wave Doppler flow profile obtained from the cardiac apex. Blood samples were obtained from a peripheral vein and examined for ET-1 and brain natriuretic peptide (BNP). Plasma was separated and stored at -20°C until analysis. 
Methods and Results
The concentration of ET-1 after bosentan administration was examined in 7 PAH patients, including 2 primary and 5 secondary cases. They were clinically assessed by pulmonary artery pressure (PAP), 6-min walk distance (6MWD) and plasma brain natriuretic peptide (BNP) concentration. Baseline ET-1 concentration was significantly higher in patients with PAH than in normal individuals (2.19±0.71 pg/ml vs 1.45±0.10 pg/ml, p<0.05) and was significantly correlated with 6MWD and BNP. A single dose of 62.5 mg bosentan in patients with PAH significantly increased plasma ET-1 concentration to 2.04 times the basal concentration (p<0.01) with a peak at 8. 
P
Statistical Analysis
Measured and calculated values are presented as the mean ± standard deviation (SD). Pearson's correlation coefficient was used to establish the association between plasma ET-1 concentration and clinical parameters. Results were considered to be statistically significant at p≤0.05.
Results
Baseline Clinical Characteristics of PAH Patients
Baseline patient characteristics are summarized in Table1. Patients included 2 idiopathic PAH and 5 secondary PAH associated with collagen disease. All patients were treated with anticoagulants and oxygen, 5 patients with diuretics and 4 patients with sildenafil. No patient was under treatment with epoprostenol.
For the assessment of severity of PAH, Doppler echocardiography, 6MWD and plasma BNP concentration were determined within 3 days before bosentan administration. Mean estimated systolic PAP was 77±30 mmHg, 6MWD was 284±111 m and mean plasma BNP was 260±295 pg/ml. The baseline plasma ET-1 concentration was significantly higher in PAH patients than in 100 healthy volunteers (2.19±0.71 pg/ml vs 1.45±0.10 pg/ml, p<0.05). Further- Correlation between pulmonary arterial pressure (PAP) and peak to base ratio of plasma endothelin (ET)-1 concentration after bosentan administration. There is a significant negative correlation between systolic PAP and peak to base ratio of plasma ET-1 concentration after bosentan administration in patients with pulmonary arterial hypertension (r=-0.75, p=0.05).
Table 2 Plasma Endothelin Concentrations After Bosentan Administration
Case no. 
Concentration of plasma ET-1 (pg/ml) (peak to base ratio (%))
Abbreviation see in Table 1 .
more, baseline plasma ET-1 concentration in PAH patients showed a significant positive correlation with plasma BNP level (Fig 1) . We, for the first time, clearly showed positive correlation between plasma ET-1 and BNP concentrations in patients with PAH.
Plasma ET-1 Concentration After Bosentan Administration
Plasma ET-1 concentration was measured at 0, 1, 3, 6 and 24 h after a single 62.5 mg dose of bosentan in 7 PAH patients ( Table 2 ). Plasma ET-1 level increased significantly after bosentan administration in all patients, and peaked at 3-24 h (mean 8.1 h). The average of peak to base ratio of plasma ET-1 concentration after bosentan administration was 204%. Interestingly, peak to base ratio of plasma ET-1 after bosentan administration correlated negatively with the severity of PAH as evaluated by systolic PAP (r=-0.75, p=0.05) (Fig 2) .
Discussion
We prescribed bosentan to 7 PAH patients including primary and secondary cases, and obtained similar effects. PAH includes primary and secondary PH. It is now clear that there are conditions within the category of secondary PH that resemble primary PH in their histopathological features and their response to treatment. 3 Plasma ET-1 concentration was reported to be elevated and correlate with the severity of the disease in patients with primary PH. 6 The current study shows a correlation between plasma ET-1 concentrations and severity of the disease in both primary and secondary PH patients.
The effect of ET-1 is mediated through ET-A and ET-B receptors. 12 Activation of ET-A receptors induces sustained vasoconstriction and proliferation of vascular smoothmuscle cells, whereas the ET-B receptor mediates pulmonary ET-1 clearance 13 and induces vasodilatation via the production of nitric oxide and prostacyclin in endothelial cells. 14 Recent experimental data using pharmacological blockade of ET-B receptors or targeting of the ET-B gene in rats suggest that stimulation of the ET-B receptor provides a net protective effect mediating vasodilatation and clearance of ET-1 from the circulation. 15 The number of ET-B receptors in endothelial cells and smooth-muscle cells is reported to increase in pathological states. 16 Previous studies showed that plasma ET-1 concentration did not increase in normal individuals after bosentan administration. 17 In the present study, all PAH patients showed significantly increased plasma ET-1concentration after bosentan administration. Loffler et al reported that the increase in plasma ET-1 concentration in rat caused by bosentan administration was most likely a result of displacement of ET-1 from ET-B receptors. 18 In addition, patients with a low PAP showed a greater response in plasma ET-1 concentration after bosentan administration than patients with a high PAP. This correlation suggests that larger numbers of ET-B receptors remain in mild PAH state than in severe PAH.
In summary, this is the first study showing that plasma ET-1 concentration increases significantly in patients with PAH after bosentan administration. Our data suggest a correlation between the response of plasma ET-1 to bosentan administration and the severity of PAH. Not only the basal concentration of plasma ET-1 but the response of plasma ET-1 to bosentan administration might be useful for determining the severity of PAH.
